logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

aRCC: front-line avelumab-axitinib tops sunitinib in JAVELIN Renal 101

Benefit observed regardless of risk group or PD-L1-positive status.